VIR beat EPS expectations by 37.56%
Feb 23, 2026, 11:35 PM
0.00%
What does VIR do
Vir Biotechnology is a San Francisco-based clinical-stage immunology company focusing on treatments for infectious diseases, with a pipeline targeting HDV, HBV, HIV, and other viruses. The company went public on October 11, 2019, and employs 587 full-time staff.
Vir Biotechnology (VIR) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Vir Biotechnology's actual EPS was -$0.31, beating the estimate of -$0.50 per share, resulting in a 37.56% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.